Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CRSP 
Crispr Therapeutics AG (CRSP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CRSP (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
28 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $82
1 Year Target Price $82
| 12 | Strong Buy |
| 5 | Buy |
| 10 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.08% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.87B USD | Price to earnings Ratio - | 1Y Target Price 82 |
Price to earnings Ratio - | 1Y Target Price 82 | ||
Volume (30-day avg) 28 | Beta 1.8 | 52 Weeks Range 30.04 - 71.13 | Updated Date 08/28/2025 |
52 Weeks Range 30.04 - 71.13 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When - | Estimate -1.4 | Actual -2.4 |
Profitability
Profit Margin - | Operating Margin (TTM) -14918.27% |
Management Effectiveness
Return on Assets (TTM) -13.05% | Return on Equity (TTM) -25.34% |
Valuation
Trailing PE - | Forward PE 23.36 | Enterprise Value 3362791143 | Price to Sales(TTM) 127.95 |
Enterprise Value 3362791143 | Price to Sales(TTM) 127.95 | ||
Enterprise Value to Revenue 96.08 | Enterprise Value to EBITDA 14.16 | Shares Outstanding 90950400 | Shares Floating 90501128 |
Shares Outstanding 90950400 | Shares Floating 90501128 | ||
Percent Insiders 1.64 | Percent Institutions 80.87 |
Upturn AI SWOT
Crispr Therapeutics AG
Company Overview
History and Background
CRISPR Therapeutics AG was founded in 2013 with the goal of leveraging CRISPR-Cas9 gene editing technology to develop transformative medicines for serious diseases. The company has achieved significant milestones in advancing its pipeline of gene-edited cell therapies and in vivo gene editing programs, including clinical trials for various indications.
Core Business Areas
- Ex Vivo Cell Therapies: CRISPR Therapeutics focuses on developing ex vivo cell therapies where patient cells are engineered outside the body using CRISPR technology and then transplanted back into the patient to treat diseases like hematologic malignancies and hemoglobinopathies.
- In Vivo Gene Editing: CRISPR Therapeutics also develops in vivo gene editing therapies, where CRISPR technology is directly delivered into the patient's body to target specific genes within cells, with applications in liver diseases, cardiovascular diseases and other genetic disorders.
- Platform Technologies: The company continues to advance its core CRISPR-Cas9 technology platform, developing new and improved gene editing tools and delivery methods to enhance the efficacy and safety of its therapies.
Leadership and Structure
The leadership team consists of Samarth Kulkarni, PhD (CEO), and other key executives. The organizational structure includes research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- CTX110: Allogeneic CAR-T cell therapy targeting CD19 for B-cell lymphomas. Competing therapies include autologous CAR-T therapies from Gilead (Kite) and Novartis. Market share data not readily available, as it is still in clinical trials, and regulatory approval is required.
- CTX130: Allogeneic CAR-T cell therapy targeting CD70 for T-cell lymphomas and solid tumors. Competitors include other companies developing novel T-cell therapies. Market share data not readily available.
- Exagamglogene Autotemcel (exa-cel) / Casgevy (partnered with Vertex): Gene-edited cell therapy for severe sickle cell disease and transfusion-dependent beta thalassemia. Competitors include bluebird bio and others developing novel gene therapies. Market share data not readily available, as it is still in clinical trials, and regulatory approval is required.
Market Dynamics
Industry Overview
The gene editing industry is rapidly growing, driven by advancements in CRISPR-Cas9 technology and the potential to treat a wide range of genetic diseases. The industry is characterized by intense competition, high R&D costs, and evolving regulatory landscape.
Positioning
CRISPR Therapeutics is a leading company in the gene editing field, with a strong intellectual property portfolio and a pipeline of promising therapeutic candidates. The company benefits from its collaboration with Vertex Pharmaceuticals.
Total Addressable Market (TAM)
The total addressable market for gene editing therapies is estimated to be in the tens of billions of dollars. CRISPR Therapeutics is positioned to capture a significant portion of this market with its diverse pipeline and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Pioneering gene editing technology
- Strong intellectual property portfolio
- Strategic collaboration with Vertex Pharmaceuticals
- Advanced clinical pipeline
- Experienced management team
Weaknesses
- High R&D costs
- Regulatory uncertainty
- Clinical trial risks
- Manufacturing complexity
- Reliance on collaboration partners
Opportunities
- Expanding therapeutic applications of CRISPR technology
- Developing next-generation gene editing tools
- Entering new strategic partnerships
- Addressing unmet medical needs
- Expanding into new geographic markets
Threats
- Competition from other gene editing companies
- Adverse clinical trial results
- Changes in regulatory landscape
- Patent disputes
- Ethical concerns regarding gene editing
Competitors and Market Share
Key Competitors
- EDIT
- NTLA
- BEAM
Competitive Landscape
CRISPR Therapeutics faces competition from other gene editing companies, including Editas Medicine (EDIT) and Intellia Therapeutics (NTLA). CRISPR Therapeutics' strengths include its collaboration with Vertex and its advanced clinical pipeline. Weaknesses include its reliance on collaboration partners and the high costs of R&D.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the advancement of its pipeline and strategic partnerships.
Future Projections: Future growth is expected to be driven by the potential commercialization of its gene editing therapies and the expansion of its pipeline.
Recent Initiatives: Recent initiatives include advancing clinical trials for its lead programs and expanding its manufacturing capabilities.
Summary
CRISPR Therapeutics is a leading company in the gene editing field, with a strong pipeline and strategic partnership with Vertex. The company's strengths lie in its pioneering technology and experienced team. However, it faces challenges related to regulatory uncertainty, high R&D costs, and competition from other gene editing companies. Successful commercialization of its therapies is crucial for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary based on source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Crispr Therapeutics AG
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-10-19 | CEO & Chairman Dr. Samarth Kulkarni Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 393 | Website https://www.crisprtx.com |
Full time employees 393 | Website https://www.crisprtx.com | ||
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.